Neurogene FY2026 Earnings Forecast Raised by HC Wainwright

Neurogene Inc. (NASDAQ:NGNE – Free Report) – Investment analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of Neurogene in a report issued on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($5.04) for the year, up from their previous forecast of ($5.44). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($5.26) per share. HC Wainwright also issued estimates for Neurogene’s Q4 2026 earnings at ($1.16) EPS, Q1 2027 earnings at ($1.18) EPS, Q2 2027 earnings at ($1.19) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.22) EPS and FY2027 earnings at ($4.80) EPS.

Neurogene (NASDAQ:NGNE – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.31.

A number of other brokerages also recently issued reports on NGNE. Guggenheim increased their price target on Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Wall Street Zen raised Neurogene from a “strong sell” rating to a “sell” rating in a report on Saturday. Canaccord Genuity Group cut their target price on Neurogene from $180.00 to $166.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a report on Thursday, October 15th. Finally, William Blair upgraded Neurogene to a “strong-buy” rating in a research report on Wednesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $79.57.

View Our Latest Research Report on Neurogene

Neurogene Stock Performance

Shares of NASDAQ:NGNE opened at $23.93 on Thursday. The company’s 50 day moving average price is $28.21 and its two-hundred day moving average price is $28.08. Neurogene has a 12-month low of $15.93 and a 12-month high of $43.66.

Hedge Funds Weigh In On Neurogene

Several large investors have recently bought and sold shares of NGNE. State of Wyoming acquired a new position in shares of Neurogene in the second quarter worth approximately $31,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Neurogene in the 3rd quarter valued at $28,000. Legal & General Group Plc bought a new stake in shares of Neurogene in the 2nd quarter valued at $35,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Neurogene by 45.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,651 shares of the company’s stock valued at $104,000 after purchasing an additional 1,136 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Neurogene during the second quarter worth $192,000. 52.37% of the stock is currently owned by institutional investors.

Neurogene News Roundup

These are some of the NGNE news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings-per-share estimates, projecting narrower losses across the periods and lifting its FY2027 estimate to a loss of $4.80 per share from $4.99. The firm maintained its Buy rating and $60 price target. HC Wainwright forecast for Neurogene
  • Positive Sentiment: Canaccord Genuity also reaffirmed its Buy rating on Neurogene, signaling continued analyst confidence. Canaccord Genuity keeps Buy rating
  • Negative Sentiment: Despite the improved estimates, HC Wainwright still expects Neurogene to report losses in 2026 and 2027, underscoring its ongoing financial risk.

About Neurogene

(Get Free Report)

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company’s lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.

Featured Stories

Earnings History and Estimates for Neurogene (NASDAQ:NGNE)

Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.